UNSPSC 51162201: Ephedrine/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE102. This VA Drug Class (RE102) classifies this compound as belonging to the group BRONCHODILATORS, SYMPATHOMIMETIC, INHALATION.

UNSPSC 51162201 Ephedrine/sodium chloride is a Commodity code under which state and local governments procure generic pharmaceuticals and over-the-counter products through cooperative purchasing frameworks. The actual work being solicited is manufacturer supply of multi-source generic drugs and OTC items with specific National Drug Codes, packaging configurations, and manufacturing certifications, distributed via authorized wholesalers to state and local government health facilities. Vendors must maintain cGMP and Drug Supply Chain Security Act compliance, hold minimum insurance coverage including $5 million commercial general liability, and demonstrate pricing flexibility through flat-price, net-price, or WAC-minus structures. Products must be available in the marketplace by specified dates and carry a minimum six-month shelf life with at least one year expiration dating from manufacture. The issuing bodies under this code include state cooperative purchasing alliances administering multi-jurisdictional procurement on behalf of participating state agencies and local government facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon. Proposals were due March 26, 2026, with a February 18, 2026 cutoff for questions. Evaluation weighted price competitiveness at 75 percent, fixed pricing at 10 percent, compliance with administrative fee format and EDI capability at 5 percent each, and agreement to a 3 percent administrative fee at 5 percent. Vendors must maintain relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with chargeback systems in place. Awarded vendors will be provided to wholesalers by May 15, 2026, with contracts effective July 1, 2026. The contract term is two years for new responders with optional extensions at MMCAP's discretion, while incumbent amendments align with existing agreement expiration dates through June 30, 2028. Performance penalties range from $200 to $1,500 per violation for issues including late reporting and missed onboarding timelines.